Salarius Pharmaceuticals, Inc. (SLRX)
NASDAQ: SLRX · Real-Time Price · USD
0.9250
+0.0423 (4.79%)
At close: Nov 26, 2025, 4:00 PM EST
0.8854
-0.0396 (-4.28%)
After-hours: Nov 26, 2025, 7:59 PM EST
Salarius Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
2
Market Cap
5.42M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 1.84M | -3.39M | -64.84% |
| Dec 31, 2020 | 5.23M | 1.77M | 51.03% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SLRX News
- 8 days ago - Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX” - GlobeNewsWire
- 14 days ago - Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger - GlobeNewsWire
- 16 days ago - Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering - PRNewsWire
- 6 weeks ago - Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements - GlobeNewsWire
- 2 months ago - Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 3 months ago - Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split - GlobeNewsWire
- 4 months ago - Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard - GlobeNewsWire
- 5 months ago - Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - GlobeNewsWire